Patient Dropouts, Other “Missing Data” To Be Addressed In FDA Guidance

FDA hopes two guidances - one on non-inferiority margins and another on how to handle missing data in clinical trials - will better direct industry in developing clinical trials and extrapolating more accurate data

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet